国家乳腺和肠道外科辅助项目-猫眼课题宝

国家乳腺和肠道外科辅助项目

批准号：

7931029

负责人：

NORMAN WOLMARK

金额：

$6.98万

依托单位：

NSABP FOUNDATION, INC.

依托单位国家：

美国

项目类别：

财政年份：

2009

资助国家：

美国

项目状态：

已结题

起止时间：

2009-09-30 至 2011-09-29

来源：

https://reporter.nih.gov/project-details/7931029

关键词：

Adjuvant Adjuvant Study Adjuvant Therapy Amenorrhea American American Cancer Society Antibodies Area Breast Calendar Canada Cancer Patient Cardiac Clinical Trials Clinical Trials Cooperative Group Clinical Trials Database Clinical Trials Design Colon Carcinoma Colorectal Colorectal Cancer Data Development Diagnostic Neoplasm Staging Disease ERBB2 gene Employee Strikes Epidermal Growth Factor Receptor Estrogen receptor positive Functional disorder Gene Expression Genes Genetic Techniques Goals Grant Health behavior outcomes Individual Institution Investigation Knowledge Laboratory Research Late Effects Lead Methods Molecular Genetics Morbidity - disease rate National Surgical Adjuvant Breast and Bowel Project Neoadjuvant Therapy North America Operative Surgical Procedures Outcome Participant Patients Persons Phase Phase III Clinical Trials Positioning Attribute Postoperative Period Predictive Value Puerto Rico Quality of life Randomized Controlled Clinical Trials Reporting Research Research Design Reverse Transcriptase Polymerase Chain Reaction Risk Science Specimen Speed Staging Surgeon Tamoxifen Techniques Therapeutic Human Experimentation Tissues Toxic effect Tumor Bank Tumor Markers Tumor Tissue Validation Vascular Endothelial Growth Factors behavioral health cancer therapy chemotherapy demographics design improved indexing malignant breast neoplasm member molecular marker novel outcome forecast prognostic response small molecule success tumor

中文摘要

翻译

美国癌症协会估计，2004年，乳腺癌或结直肠癌的发病率将超过35万美国人和近10万人将死于这些疾病。国家外科辅助剂乳腺和肠道计划(NSABP)是一个拥有近200名成员的多中心临床合作试验小组这些机构遍布美国、加拿大和波多黎各。该项目的主要研究目标 NSABP进行旨在改善患者生存和生活质量的治疗研究患有乳腺癌或结直肠癌。这一目标是通过进行最终的第三阶段试验和导致它们的发展努力。在2002和2003历年，NSABP进入了10,270 乳腺癌患者和962例结直肠癌患者进入辅助治疗试验。根据NCI的数据，这代表了进入NCI的乳腺癌患者的和结直肠癌患者的78% 赞助协作组第三阶段乳剂或结直肠佐剂试验。NSABP整合了将关键行为和健康结果纳入其第三阶段试验，为传统终端提供附加值无病生存和总存活率。NSABP还联合开展相关的实验室研究其临床试验旨在改进评估预后和预测疗效的方法治疗的目的是优化对个别患者的治疗。在拟议的项目期间，我们的目标将是继续改进乳腺癌和结直肠癌的治疗方法。通过开发和实施精心设计的第三阶段辅助治疗试验，将进行我们在北美拥有广泛的附属会员网络。

英文摘要

The American Cancer Society estimated that in 2004, breast or colorectal cancer would strike over 350,000 Americans and close to 100,000 people would die from these diseases. The National Surgical Adjuvant Breast and Bowel Project(NSABP) is a multi-center clinical cooperative trials group with nearly 200 member institutions located throughout the US, Canada and Puerto Rico. The primary research objective of the NSABP is to conduct therapeutic research designed to improve the survival and the quality of life for persons with breast or colorectal cancer. This goal is achieved through the conduct of definitive phase III trials and the developmental efforts that lead to them. In calendar years 2002 and 2003, the NSABP entered 10,270 breast cancer patients and 962 colorectal cancer patients into adjuvant therapy trials. According to NCI data, this represents 64% of the breast cancer patients and 78% of the colorectal cancer patients entering NCI sponsored phase III cooperative group adjuvant breast or colorectal adjuvant trials. The NSABP integrates key behavior and health outcomes into its phase III trials to provide added value to the traditional endpoints of disease-free and overall survival. The NSABP also conducts correlative laboratory research in conjunction with its clinical trials designed to improve methods of assessing prognosis and predicting response to treatment with the aim of optimizing therapy for individual patients. In the proposed project period our aim will be to continue to improve breast and colorectal cancer therapies through the development and conduct of well-designed Phase III adjuvant therapy trials which will be carried out at our extensive network of affiliated members throughout North America.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文